NURIX THERAPEUTICS, INC. Accounts Receivable
NURIX THERAPEUTICS, INC. (NRIX) had Accounts Receivable of $19.00 million as of 2025-05-31, per its 10-Q filed 2025-07-09.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2025-07-09
- 2025-05-31: Accounts Receivable, after Allowance for Credit Loss, Current $19.00M.
- 2024-11-30: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
- 2023-08-31: Accounts Receivable, after Allowance for Credit Loss, Current $2.00M.
- 2022-11-30: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2025-05-31 | $19.00M 10-Q · filed 2025-07-09 |
| 2024-11-30 | $0.00 10-Q · filed 2025-07-09 |
| 2023-08-31 | $2.00M 10-Q · filed 2023-10-12 |
| 2022-11-30 | $0.00 10-Q · filed 2023-10-12 |
| 2021-05-31 | $2.54M 10-Q · filed 2021-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |